Fluvoxamine in the treatment of severe depression

Research output: Contribution to journalReview articlepeer-review

Abstract

Approximately one-third of depressed patients suffer from severe depression The selective serotonin reuptake inhibitors (SSRIs) have clear advantages over the tricyclic antidepressants with regard to their safety and tolerability profile. However, there is some debate as to whether they are as effective as the tricyclic antidepressants for the treatment of severe depression. The efficacy of fluvoxamine has been documented and has been shown to be more effective than placebo and at least as effective as imipramine, clomipramine, amitriptyline, desipramine and amineptine in patients with severe depression. Since SSRIs have a better tolerability profile, are safe in overdose, and some of them (e.g. fluvoxamine) have been found to be as effective as tricyclic antidepressants in severe depression, they might be considered as a first option in the treatment of depression, including severe depression.

Original languageEnglish
Pages (from-to)115-119
Number of pages5
JournalPrimary Care Psychiatry
Volume9
Issue number4
DOIs
StatePublished - 2004
Externally publishedYes

Keywords

  • Fluvoxamine
  • Selective serotonin inhibitors
  • Severe depression

Fingerprint

Dive into the research topics of 'Fluvoxamine in the treatment of severe depression'. Together they form a unique fingerprint.

Cite this